Weight Loss
care that delivers

Compounded Medication Disclaimer

Compounded semaglutide and compounded tirzepatide are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded medications have not undergone FDA review for safety, effectiveness, or manufacturing consistency.

Licensed healthcare providers may prescribe compounded medications when they determine a customized treatment is medically appropriate based on an individual's clinical needs.

Join Luma's Role

Join Luma is a telehealth platform that connects eligible patients with licensed healthcare providers for medical evaluations.

Join Luma does not practice medicine, manufacture medications, or operate a pharmacy. All prescribing decisions are made solely by the treating healthcare provider. If treatment is prescribed, medications are dispensed through appropriately licensed U.S. pharmacies.

Eligibility

Treatment eligibility is determined individually following a comprehensive medical evaluation.

Healthcare providers generally consider factors such as:

• Body Mass Index (BMI)
• Weight-related medical conditions
• Current medications
• Medical history
• Treatment goals
• Overall health status

Not every patient is an appropriate candidate for GLP-1 therapy, and prescriptions are not guaranteed.

Intended Use

Semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP and GLP-1 receptor agonist. These medications may be prescribed as part of a comprehensive weight management program that includes healthy nutrition, increased physical activity, and ongoing medical supervision.

How These Medications Work

GLP-1 medications work by mimicking naturally occurring hormones involved in appetite regulation and blood sugar control. Depending on the medication prescribed, they may help:

• Reduce appetite
• Increase feelings of fullness
• Slow stomach emptying
• Improve insulin response
• Reduce glucagon release
• Support long-term weight management when combined with lifestyle changes

Individual results vary and cannot be guaranteed.

Do Not Use These Medications If You:

• Have a personal or family history of medullary thyroid carcinoma (MTC).
• Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Have previously experienced a serious allergic reaction to semaglutide, tirzepatide, or any ingredient in the prescribed formulation.

Before Starting Treatment

Tell your healthcare provider if you:

• Have a history of pancreatitis.
• Have kidney disease or liver disease.
• Have gallbladder disease.
• Have severe gastrointestinal disorders or delayed stomach emptying (gastroparesis).
• Have diabetic retinopathy or vision problems.
• Have heart disease or cardiovascular conditions.
• Have depression, anxiety, or a history of suicidal thoughts.
• Are pregnant, planning to become pregnant, or breastfeeding.
• Take insulin, sulfonylureas, or any prescription medications, over-the-counter medications, vitamins, herbal products, or supplements.

Providing a complete medical history helps your provider determine whether treatment is appropriate.

Important Warnings & Precautions

Serious side effects may occur, although they are uncommon.

Potential risks include:

• Thyroid C-cell tumors (observed in animal studies)
• Pancreatitis
• Severe nausea and vomiting
• Delayed stomach emptying (gastroparesis)
• Gallbladder disease
• Acute kidney injury, particularly with dehydration
• Low blood sugar when used with insulin or certain diabetes medications
• Serious allergic reactions
• Changes in vision in patients with diabetes
• Increased heart rate
• Mood changes, depression, or suicidal thoughts in susceptible individuals

Seek immediate medical attention if you develop severe abdominal pain, difficulty breathing, swelling of the face or throat, persistent vomiting, or symptoms of a severe allergic reaction.

Administration

Semaglutide and tirzepatide are typically administered as subcutaneous injections once weekly.

Inject your medication on the same day each week unless instructed otherwise by your healthcare provider.

Recommended injection sites include:

• Abdomen
• Thigh
• Upper arm

Rotate injection sites regularly to minimize irritation.

Never increase, decrease, or discontinue your medication without consulting your healthcare provider.

Common Side Effects

The most frequently reported side effects include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Indigestion
• Heartburn
• Bloating
• Belching
• Fatigue
• Headache
• Dizziness
• Injection site irritation
• Decreased appetite

Most side effects are mild to moderate and improve as your body adjusts to treatment.

Drug Interactions

GLP-1 medications may affect the absorption of oral medications because they slow stomach emptying.

Inform your healthcare provider about all:

• Prescription medications
• Over-the-counter medications
• Vitamins
• Herbal supplements
• Dietary supplements

Additional monitoring may be required if you use insulin or medications that lower blood sugar.

Pregnancy & Breastfeeding

These medications are generally not recommended during pregnancy or while breastfeeding.

If you become pregnant, plan to become pregnant, or begin breastfeeding during treatment, notify your healthcare provider promptly.

Reporting Side Effects

If you experience unexpected or concerning side effects, contact your healthcare provider immediately.

Suspected adverse events may also be reported to the FDA MedWatch Program by calling 1-800-FDA-1088 or visiting www.fda.gov/medwatch.

Commitment to Patient Safety

Your safety is our priority.

Join Luma encourages all patients to communicate openly with their healthcare provider, attend recommended follow-up appointments, and report any new or worsening symptoms during treatment.

Every treatment plan is individualized, and outcomes vary based on each patient's health, adherence to treatment, and lifestyle factors.

Trademark Notice

Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company.

Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S.

Join Luma is not affiliated with, sponsored by, or endorsed by Eli Lilly and Company, Novo Nordisk A/S, or any other pharmaceutical manufacturer. All trademarks remain the property of their respective owners.

Questions?

If you have questions regarding your treatment or your Join Luma account, please contact support@joinluma.com.